A Safety Study of EPC2407, A Anti-Cancer Drug With Vascular Disrupting Activity: In Patients With Advanced Cancer

Inclusion Criteria

• •1. Histologically or cytologically confirmed solid tumor or lymphoma,which has progressed on standard therapies, for which effective therapy is not available or for patients who are unwilling to undergo such therapies.
• •2. Males and Females at least 18 years of age
• •3. Laboratory data as specified below (according to the site's clinical laboratory ranges for normal):
• •i. Hematology: ANC \>1500 cells/mm3, platelet count \>100,000 cells/mm3 and Hemoglobin \> 9 gm/L ii. Hepatic: Direct bilirubin \<1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 2.5 X ULN. For patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \< 5.0 X ULN iii. Renal: serum creatinine WNL or creatinine clearance \>60 mL/min
• •4. 12-lead electrocardiogram (ECG) QT intervals: QTc ≤ 450 msec for men and ≤ 470 msec for women.
• •5. Estimated life expectancy of at least 3 months
• •6. ECOG Performance Status \< or = 1
• •7. Previously treated CNS disease allowed if treatment completed and stable for 4 weeks.
• •8. For men and women of child-producing potential - willingness to employ appropriate contraceptive methods (including abstinence) during the study
• •9. Ability to understand the requirements of the study, provide written informed consent and authorization of use and disclosure of protected health information, and agree to abide by the study restrictions and to return for the required assessments
• •10. Cardiac ejection fraction ≥50% by 2D Echocardiogram or \> institutional lower limits of normal